AMPLIFY Phase III trial results demonstrated statistically significant and clinically meaningful improvement in progression-free survival for Calquence combinations
Approval based on AEGEAN Phase III trial results which showed a 32% reduction in the risk of recurrence, progression or death vs. neoadjuvant chemotherapy alone
The introduction of Coveris’ sleeve-to-sleeve PCR model complements sectors such as bottling where an established recycling infrastructure exists
L-HPC was independently developed by Shin-Etsu Chemical as a disintegrant for tablets
Will add UNLOXCYT (cosibelimab-ipdl), the first and only FDA-approved anti-PD-L1 treatment for metastatic or locally advanced cutaneous squamous cell carcinoma (cSCC) to Sun Pharma's global onco-derm franchise
We will continue to expand our range of purified excipients, offering pharmaceutical companies a dependable partner
Based on ECHO Phase III trial results which showed more than 16 months of progression-free survival improvement vs. chemoimmunotherapy alone
In 2023, Endox had revenues of approximately SEK 65 million
The combined entity will leverage its complementary strengths to deliver unparalleled solutions in protein purification and stabilization
Subscribe To Our Newsletter & Stay Updated
